Images of the brain's fastest signals reveal an electromagnetic marker that predicts a patient's response to a fast-acting antidepressant. Such use of a brain scanner could someday minimize trial-and-error prescribing and speed delivery of care, say researchers. Depressed patients showed increased activity in a mood-regulating hub near the front of the brain while viewing flashing frightful faces -- the more the increase, the better their response to an experimental fast-acting medication called ketamine.

Share:

Total shares:

FULL STORY

The degree of increased activity in a mood regulating hub called the anterior cingulate (arrow) in response to flashing frightful faces predicted a patients' response to a fast-acting antidepressant mechanism. MEG data superimposed on anatomical MRI image of the brain.

Credit: NIMH Mood and Anxiety Disorders Program

The degree of increased activity in a mood regulating hub called the anterior cingulate (arrow) in response to flashing frightful faces predicted a patients' response to a fast-acting antidepressant mechanism. MEG data superimposed on anatomical MRI image of the brain.

Credit: NIMH Mood and Anxiety Disorders Program

Images of the brain's fastest signals reveal an electromagnetic marker that predicts a patient's response to a fast-acting antidepressant, researchers have discovered.

"Such biomarkers that identify who will benefit from a new class of antidepressants could someday minimize trial-and-error prescribing and speed delivery of care for what can be a life-threatening illness," said Carlos Zarate, M.D., of the National Institute of Mental Health (NIMH), Mood and Anxiety Disorders Program.

In the new study at the National Institutes of Health in Bethesda, MD, depressed patients showed increasing activity in a mood-regulating hub near the front of the brain while viewing flashing frightful faces – the more the increase, the better their response to an experimental fast-acting medication called ketamine. By contrast, healthy controls showed decreasing activity in this brain area under the same conditions.

Two years ago, Zarate and colleagues reported that ketamine, which targets the brain chemical glutamate, can lift depressions in just hours, instead of the weeks it takes conventional antidepressants, which work through the brain chemical serotonin. Evidence suggests that glutamate likely acts closer to the source of the depression than serotonin, and is not dependant on slower mechanisms, such as the synthesis of new neurons.

Earlier imaging studies with conventional antidepressants had hinted that increased activity of the mood-regulating hub, called the anterior cingulate cortex (ACC), signals a better response.

To find out if ACC activity might also forecast response to glutamate-targeting medications, the NIMH researchers imaged the brain activity of 11 depressed patients and 11 healthy participants, using magnetoencephalography (MEG). This imaging technology can non-invasively detect brain electromagnetic activity lasting only milliseconds – the speed of communications in neural circuits – whereas other functional brain imaging techniques can only capture activity that last seconds or minutes, and some involve radiation exposure.

This precise timing enabled the MEG scanner to capture the brain's split-second responses to rapidly flashing pictures of fearful faces, a task known to activate the ACC. While healthy participants' ACC activity dropped off as they quickly habituated to the faces, patients' ACC activity showed an opposite trend. The more robust this increase, the more symptoms improved just four hours after a patient received a single infusion of ketamine.

"The ACC may be slow to respond, but not completely impaired, in patients who respond to ketamine," explained Cornwell.

The lag in ACC activity could be a window into the dysfunctional workings of the glutamate-related circuitry targeted by the medication, the researchers suggest. Ketamine's side effects make it a poor candidate for becoming a practical antidepressant, but the new findings are helping to focus the search for new treatments that work through the same mechanism, they say.

July 29, 2015  Viewing aquarium displays led to noticeable reductions in blood pressure and heart rate, a research team found in the first study of its kind. They also noted that higher numbers of fish helped to ... read more

July 31, 2015  Perfectionistic concerns have a positive relationship with overall burnout and symptoms of burnout, research has found. Perfectionistic concerns can create stress, interfere with relationships and ... read more

July 30, 2015  As high school and college athletes hit the fields and courts in pre-season practice, concussion awareness should be part of their education, experts say, as most concussions happen during practice ... read more

Oct. 20, 2014  A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of -- and ahead of -- its other antidepressant effects. Within 40 minutes after a single infusion of ... read more

Feb. 4, 2013  A boost of activity at the back of the brain while processing emotional information predicted depressed patients' responses to an experimental rapid-acting antidepressant. The potential ... read more

Dec. 12, 2012  A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward ... read more